Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma

Publisher： Karger

E-ISSN： 1421-9794|58|6|468-474

ISSN： 0009-3157

Source： Chemotherapy, Vol.58, Iss.6, 2013-03, pp. : 468-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

By Randrup Hansen Caroline   Grimm Daniela   Bauer Johann   Wehland Markus   Magnusson Nils E.  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 461-461

MDPI

Access to resources Recommend Favorite

Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 485-491

Karger

Access to resources Recommend Favorite

Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma?

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-06 ,pp. : 200-205

Karger

Access to resources Recommend Favorite

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-12 ,pp. : 207-213

Karger

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite